References
- Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendation for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheum. 2016; 68:282–98.
- Maksymowych WP. Disease modification in ankylosing spondylitis. Nat Rev Rheumatol. 2010; 6:75–81.
- Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, et al. Discovery of a cytokine and its receptor by function screening of extracellular proteome. Science. 2008; 320:807–11.
- Chihara T, Suzu S, Hassan R, Chutiwitoonchai N, Hiyoshi M, Motoyoshi K, et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 2010; 17:1917–27.
- Wei S, Nandi S, Chitu V, Yeung Y-G, Yu W, Huang M, et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor mediated regulation of myeloid cells. J Leukoc Biol. 2010; 88:495–505.
- Chemel M, Le Goff B, Brion R, Cozic C, Berreur M, Amiaud J, et al. Interleukin 34 expression is associated with synovitis in rheumatoid arthritis patients. Ann Rheum Dis. 2012; 77:150–4.
- Tian Y, Shen H, Xia L, Lu J. Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interleukin-17 production. J Interferon Cytokine Res. 2013; 33:398–401.
- Moon S-J, Hong Y-S, Ju JH, Kwok S-K, Park S-H, Min J-K. Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis. J Rheumatol. 2013; 40:1842–9.
- Zhang F, Ding R, Li P, Ma C, Song D, Wang X, et al. Interleukin-34 in rheumatoid arthritis: potential role in clinical therapy. Int J Clin Exp Med. 2015; 8:7809–15.
- Wang S-L, Zhang R, Hu K-Z, Li M-Q, Li Z-C. Interleukin-34 synovial fluid was associated with knee osteoarthritis severity: a cross-sectional study in knee osteoarthritis patients in different radiographic stages. Dis Markers 2018; 2018:2095480. doi: 10.1155/2018/2095480
- Clavel G, Thiolat A, Boissier MC. Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Joint Bone Spine. 2013; 80:449–453.
- Mou Y-K, Zhang P-P, Li Q-X, Lin Z-M, Liao Z-T, Wei Q-J, Gu J-R. Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes. Clin Rheumatol. 2015; 34:1085–9.
- Chen C-H, Chen H-A, Liao H-T, Liu C-H, Tsai C-Y, Chou C-T. Soluble receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol. 2010; 29:1155–61.
- Feydy A, Lavie-Brion MC, Gossec L, Lavie F, Guerini H, Nguyen C, et al. Comparative study of MRI and power Doppler ultrasonography of the heel in patients with spondyloarthritis with and without heel pain and in controls. Ann Rheum Dis. 2012; 71:498–503.
- Kamel M, Eid H, Mansour R. Ultrasound detection of heel enthesitis: a comparison with magnetic resonance imaging. J Rheumatol. 2003; 30:774–8.
- Li N, Jiang L, Cai Y, Liu JY, Zhao T, Kong N, et al. The correlation between interleukin-34 and bone erosion under ultrasound in rheumatoid arthritis. Mod Rheumatol. 2019; 30:269–75.
- Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Ann Intern Med. 2015; 162:55–63.
- Schmidt SAJ, Lo S, Hollestein LM. Research techniques made simple: sample size estimation and power calculation. J Invest Dermatol. 2018; 138:1678–82.
- van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27:361–8.
- Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039–49.
- Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34:505–14.
- Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al. EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis. 2009; 68:8–17.
- Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010; 69:483–9.
- 中华医学会骨科学分会 [Chinese Medical Association Orthopaedic Branch]. 骨关节炎诊治指南(2007年版) [Guideline for diagnosis and treatment of osteoarthritis (2007 edition)]. 中华 骨科杂志 [Chin J Orthop]. 2007; 27:793–6. [in Chinese]
- Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990; 33:1601–10.
- Balint PV, Kane D, Wilson H, Mclnnes IB, Sturrock RD. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis. 2002; 61:905–10.
- Zhao W, Huang F. 细胞核因子κB 受体活化因子配基在强直性脊 柱炎的表达及意义 [Expression and significance of nuclear factor κB receptor activator ligand in ankylosing spondylitis]. The role of RANKL in the pathogenesis of peripheral joint bone destruction in ankylosing spondylitis. Medical J Chin PLA. 2004; 29:482–5. [English title and abstract, article in Chinese]
- Mori H, Kitazawa R, Mizuki S, Nose M, Maeda S, Kitazawa S. RANKL ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem Cell Biol. 2002; 117:283–92.
- Chen Z, Buki K, Vääräniemi J, Gu G, Väänänen HK. The critical role of IL-34 in osteoclastogenesis. PLoS One. 2011; 6:e18689. doi: 10.1371/journal.pone.0018689
- Baud’huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, et al. Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol. 2010; 221:77–86.